The implementation of potential new step-up or stepdown treatment recommendations in response to current guidelines is one of the main challenges currently faced in actual daily practice settings. In the present narrative review, we aim to discuss the relevance of these step-up and step-down proposals at the patient level in daily clinical practice. In particular, we aim to review the challenges associated with inhaled maintenance therapy for chronic obstructive pulmonary disease (COPD) in four clinical scenarios. First, we discuss the step up from single to double bronchodilation, including current controversies regarding the addition of a second bronchodilator versus initial treatment with two bronchodilators. Second, we discuss the step up from double bronchodilation to triple therapy while challenging current indications for inhaled steroid therapy and discussing triple therapy designs. Third, we discuss the step down from triple therapy to double bronchodilation while evaluating the effect of this downshift in risk categories on the patient according to the new classifications. Finally, we discuss the step down from double to single bronchodilation, with a special focus on safety. We believe this review will help to highlight the most relevant discussion points regarding the treatment of COPD in a manner that will stimulate and guide related clinical research.
INTRODUCTION
In recent years, an increased understanding of chronic obstructive pulmonary disease (COPD) and a considerable expansion of therapeutic options have contributed to significant changes in the management of affected patients. This increased understanding has led to the greater acceptance of two strategies for disease management. The strategy proposed by the Global Initiative for Obstructive Lung Disease (GOLD) is based on the three main variables of pulmonary function, symptoms and exacerbations. 1 By contrast, the algorithm underlying the Spanish proposal (which has since been extended to other countries) is based on clinical phenotypes. 2 Both approaches have similarities and differences, as well as advantages and disadvantages. 3, 4 The 2017 updates of both strategies reveal progressive approaches, 5, 6 and both share the goal of increased treatment individualization with the aim of further advances.
In this context, although several reports have underscored the importance of various pharmacological response factors, such as sex-related effects, 7, 8 biologicalfunctional behaviour 9 or COPD aetiology, 10, 11 clinicians may face a range of truly challenging clinical scenarios when stepping up or down in different patient populations, with a significant degree of uncertainty in the clinical decision-making process.
In the present narrative review, we aim to focus on these step-up and step-down proposals and to discuss their relevance and main controversies at the patient level in daily clinical practice. In particular, we aim to review the challenges of inhaled maintenance therapy for COPD in four clinical scenarios: (i) a step up from single to double bronchodilation, (ii) a step up from double bronchodilation to triple therapy, (iii) a step down from triple therapy to double bronchodilation and (iv) a step down from double to single bronchodilation. Of note, patient-level characteristics may clearly influence the therapeutic response. Unfortunately, a comprehensive picture is not yet available; however, it is probable that 'omics' and systems biology approaches will finally help us understand individual responses in the coming years. At present, we believe that our following discussion and arguments will highlight current needs to encourage patient-centred clinical research.
STEP UP FROM SINGLE TO DOUBLE BRONCHODILATION
Studies in recent decades have established long-acting bronchodilators (LABD) as the mainstay of treatment for COPD. 1, 2 The recommendations to step up to double bronchodilation have led to three key issues that must be clarified: the indications for a step up to double bronchodilation, the indications for first-line treatment with double bronchodilation and the potential modulatory role of pulmonary rehabilitation. Additionally, the potential adverse effects of increasing bronchodilator therapy should also be considered (see the Step down from double to single bronchodilation section).
When to step up from single to double bronchodilation
Currently, an overwhelming amount of scientific evidence supports the recommendations in favour of double bronchodilator therapy for COPD. 12 According to a recent systematic review, 13 at least 26 clinical trials with 24 338 patients have used different inhaled therapies and objectives to conduct detailed investigations of the efficacy and safety of double bronchodilation. Consequently, current recommendations suggest starting with monotherapy and progressing to double therapy in patients who remain symptomatic or starting with double bronchodilator therapy for patients with severe breathlessness.
1 Notably, we must remember that these trials have been designed to compare the average improvements achieved by patients at the cohort level. However, at the patient level, the responses vary considerably, 13 and only a few studies have used a patient-based analysis to evaluate individual responses to treatment and identify the responders.
In this light, one of the most relevant reports was published by Donohue et al.
14 The authors evaluated the functional response to double bronchodilation (umeclidinium/vilanterol) as a function of the response to single bronchodilation, using an increase of >12% and >200 mL in the trough forced expiratory volume in the first second (FEV 1 ) as a marker of a positive response. They found that approximately one-third of patients responded positively to both LABD, another one-third responded positively only to one agent and the remainder did not respond positively to either LABD. Interestingly, the former one-third of patients also had stronger responses to double bronchodilation.
The above-mentioned observation of different responses to LABD, either alone or in combination, leads to the hypothesis that the response to single bronchodilation may be used to identify candidates for double bronchodilation. This idea is interesting as we could potentially identify patients by evaluating bronchodilator responses in a bronchodilator test. Unfortunately, studies regarding the ability of the response to this test to predict a response to LABD have reported conflicting results. [15] [16] [17] [18] Two additional studies have evaluated differences in responses to double bronchodilation according to sex 8 or the baseline disease severity, as measured by the COPD Assessment Test. 19 Interestingly, the authors of the latter article observed a greater response to double bronchodilation among patients with more severe disease impact, thus supporting the recommendation of GOLD to administer double bronchodilator therapies to more symptomatic patients. In general, the identification of treatment response to double bronchodilation constitutes one of the current challenges that clinicians face.
When to administer double bronchodilation as a first-line therapy
The existing guidelines recommend that a patient be initially treated with a single LABD, with a step up to two LABD if symptoms or exacerbations persist. 20 Additionally, the GOLD recommendations suggest a firstline double LABD strategy for highly symptomatic patients. Although the threshold has not been clearly established, this approach of increased treatment intensity in response to disease impact is reasonable; however, it can be challenged with an alternative reasoning.
This alternative reasoning can be attributed to the Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial, 21 which aimed to evaluate the impact of tiotropium on the rate of FEV 1 decline. Despite the overall negative outcome, the subgroup analyses revealed that those with less advanced lung disease [22] [23] [24] [25] appeared to obtain the benefit of reducing FEV 1 decline, supporting the relevance of early treatment. 26 This idea is compelling, as later studies found that the FEV 1 decline may be more rapid during early stages. [27] [28] [29] [30] [31] Therefore, if our objective is to alter the natural course of the disease by reducing the rate of FEV 1 decline, then the approach should comprise double bronchodilator treatment during the early stages of disease to slow progression, followed by either single or double bronchodilator therapy during more advanced stages according to the need for symptom control. We note that clinical trials have not yet addressed the long-term effects of double LABD therapy in terms of FEV 1 decline and therefore this hypothesis cannot be confirmed to date. An UPLIFTlike trial with two LABD would allow us to confirm or discard this hypothesis and is therefore strongly needed. To make things more complex, a recent clinical trial comparing two double bronchodilation combinations highlighted the fact that individual patients may respond differently to different bronchodilators, 32 confirming the individualized response observed by others.
14 Therefore, future trials should evaluate the long-term impact of double bronchodilation in different patient types.
Double bronchodilation and pulmonary rehabilitation
Interestingly, the GOLD document recommends the addition of a second bronchodilator as the logical stepup to single-agent bronchodilation. 1 However, respiratory rehabilitation has been shown to yield relevant clinical benefits to patients with a good efficacy/safety profile. [33] [34] [35] [36] [37] [38] These findings have led clinicians to debate whether an increase to a second LABD or implementation of a respiratory rehabilitation programme would be the best strategy for a patient with persistent symptoms. Even considering the limitations of pulmonary rehabilitation in practice, that is the availability of resources, the percentage of responders and the maintained effect in the long term, 39, 40 knowing the impact of exercise programmes as compared with double bronchodilation would probably help advance individualized therapy at the patient level. Unfortunately, no clinical trial has yet addressed this issue, establishing another area for research.
STEP UP FROM DOUBLE BRONCHODILATION TO TRIPLE THERAPY
Scaling to triple therapy is increasingly a source for debate, especially with the advent of triple therapy in a single inhaler. According to the 2017 GOLD document, the combination of a long-acting muscarinic antagonist (LAMA), a long-acting β 2 -agonist (LABA) and an inhaled corticosteroid (ICS) would most commonly involve the addition of an ICS for patients experiencing frequent exacerbations despite correct bronchodilator treatment, as well as in patients with asthma and COPD overlap (ACO). 1 Here, the appropriateness of these indications, the role of peripheral blood eosinophil counts as a predictive biomarker for the use of ICS, 41 the design of a triple therapy regimens 42 and the role of co-morbidities deserve a comment.
Indication of ICS for the treatment of frequent exacerbators
The evaluation of patients experiencing frequent exacerbations has revealed two main controversies. First, the concept of a frequent exacerbator requires re-evaluation. This was largely based on the findings of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study, a large observational, prospective, cohort study following 2138 patients over 3 years, which identified one group of patients experiencing persistent exacerbations during a 3-year period, despite receiving active treatment. 43 However, current guidelines have simplified the concept by limiting the evaluation to only the prior year, regardless of treatment status. Consequently, this restriction may lead to the misclassification of patients. This was recently shown in the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS), 44 another prospective cohort following up 2981 patients for 3 years. By using a prospective evaluation, the authors were able to show an inconsistent exacerbation pattern in 41% of the cohort. Similarly, the ECLIPSE cohort presented an inconsistent exacerbation pattern in 65% of the patients. 43 Interestingly, in the ECLIPSE cohort, 17% of patients changed from infrequent to frequent exacerbators and 39% from frequent to infrequent between years 1 and 2 of follow-up. 45 Notably, when ECLIPSE tried to identify the clinical predictors of exacerbations during the following year at the patient level, the researchers were unable to identify a clinical trait that clearly predicts an imminent change in exacerbation frequency category. 45 In other words, although the number of previous exacerbations is a good predictor of subsequent exacerbations at a cohort level, 43 this parameter does not seem to support therapeutic decisions at the patient level. Therefore, it remains unknown whether a patient who experiences two exacerbations within 1 year is experiencing a punctual increase as part of the natural, variable presentation of the disease or if the episodes represent a true worsening of COPD, that would require re-evaluation of the treatment strategy. 46 Second, even if we accept the frequent exacerbator concept, the notion that ICS must be added to the treatment regimen of a patient with persistent exacerbations despite receiving double bronchodilation must be revisited. 47 A patient with persistent exacerbations despite receiving appropriate medical treatment, using a correct inhalation technique, and exhibiting good treatment adherence presents a significant challenge. These persistent exacerbators 47 may have one or more of several potentially treatable extrapulmonary comorbidities associated with exacerbations, for example overlap with asthma, bronchiectasis, airway chronic colonization, heart conditions, heart conditions, gastrooesophageal reflux or immune deficiencies. Interestingly, of these co-morbid conditions, only the overlap with asthma is treated with ICS. Therefore, cases with persistent exacerbations must be approached systematically by a specialized respiratory medicine department to determine the conditions influencing the incidence of exacerbations and thus administer the correct preventive treatment. Additionally, other disease features such as FEV 1 decline, lifestyle and coping, medication adherence or symptoms may also contribute to disease complexity. The correct systematic diagnostic approach towards identifying the best treatment for these patients must be defined in the near future.
Indication of ICS for overlapping asthma and COPD
Although ACO is another relevant indication for ICS use, 1,2 at least three controversial aspects should be considered. First, the concept of ACO is poorly defined. ACO could encompass four different situations (Fig. 1) and may indicate either the presence of both diseases in one patient or a single disease with a peculiar clinical presentation. This distinction is beyond semantic, as a patient with two diseases could potentially be treated with agents for both conditions if indicated (e.g. biological therapy or phosphodiesterase inhibitors). However, therapeutic decisions become more controversial for a patient with a single disease with a peculiar clinical presentation, as new clinical trials would be needed for this specific indication. The most recent Spanish proposal, although controversial, encompasses both concepts associated with ACO. 48 Second, the identification of ACO remains controversial. Several biomarkers have been associated with ACO, including a positive bronchodilator test, bronchial hyper-responsiveness or peripheral blood or sputum eosinophilia. Although several observational studies have indicated interrelationships among these biomarkers at the cohort level, 49, 50 multiple studies have indicated mismatches among these biomarkers at the patient level. [51] [52] [53] Consequently, the biomarkers needed to identify this specific population remain unknown.
Third, the treatment of ACO remains controversial. The asthma component has led clinicians to assume that all affected patients should receive ICS therapy. Despite the likely truth of this assumption, supportive evidence from clinical trials is not available because of the lack of a consensus definition or a method of patient identification. In fact, an earlier observational study highlighted potential controversies regarding the role of ICS for ACO. 54, 55 In summary, despite the clinical reality of ACO, these different disease concepts of ACO based on varying diagnostic criteria [56] [57] [58] strongly underscore the need for clarification and research on this issue. This condition must be adequately defined at the individual patient level, and a consensus must be reached on diagnostic criteria and patient identification before clinical trials can be conducted to determine the optimal treatment.
Peripheral blood eosinophils as a marker of responsiveness to ICS
At least four post hoc analyses of major clinical trials [59] [60] [61] [62] [63] have identified blood eosinophils as a potential biomarker for ICS response. However, three controversies must be addressed at the patient level. First, the stability of the blood eosinophil population over time remains to be determined. A novel marker of ICS treatment should be sufficiently stable to reflect the disease status over time. However, the results of several studies are controversial, and a recent long-term follow-up study reported that this stability decreased over time and appeared to be significantly affected by age and sex. 64 Second, the accuracy of the blood eosinophil population as a surrogate marker of the corresponding airway population remains a challenge. Although some studies suggested a relationship, 65 further data analysis revealed a weak correlation 53, 66 and a poor diagnostic profile. 67 Third, an understanding of eosinophil physiology may be more important than a simple count. The eosinophil is an immune cell with a complex physiology that involves different activation marker pathways and interactions with other types of immune cells. 68 Interestingly, a recent publication described new subtypes of eosinophils that exert a regulatory, rather than effector, role and are indistinguishable in a simple blood cell count analysis. 69 Therefore, future studies will need to evaluate blood eosinophils along with activation markers in specific clinical scenarios to finally determine their role in patient management. 70 
Triple therapy design
The introduction of double bronchodilation provides a new option to build triple therapy comprising a fixed LABA/LAMA combination with an ICS in a second inhaler. This has led to questions regarding the most appropriate strategy. Given the lack of clinical trials that directly compare both possible triple therapies, a recent opinion piece suggested the potential benefits of using LABA/ICS + LAMA for asthma and LABA/LAMA + ICS for COPD. 42 This scenario will likely change in the near future once triple therapies are available in a single inhaler, as clinically, combined treatments have been associated with improved adherence and subsequent clinical and economic benefits. 71 Recently, the TRIBUTE study, a randomized clinical trial comparing triple therapy with formoterol/ glycopyrronium/beclomethasone versus double bronchodilator therapy with indacaterol/glycopyrronium provided further evidence on the improvements of stepping up to triple therapy. 72 Additionally, the The patient has two diagnoses
The patient has one diagnosis with a peculiar clinical presentation Stepping up and down COPD therapies IMPACT trial comparing fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/umeclidinium or umeclidinium/vilanterol over a 52-week treatment period was been recently published. 73 Nonetheless, the potential risks of over prescribing more intense therapies in a single inhaler may also to lead to overtreatment. Therefore, treatment decisions should be patient-tailored.
The role of co-morbidities
Finally, there are a number of co-morbidities described that should probably be considered when evaluating stepping up to triple therapy, for example previous pneumonia or osteoporosis. The debate of pneumonia and ICS prescription would need an ad hoc review. Briefly, from the publication of the results of the TOwards a Revolution in COPD Health (TORCH) trial, 74 several studies have shown a consisting relationship between lower respiratory tract infections and the use of ICS. This relationship is under study, as it seems to be influenced by several factors, including the molecule, the dose or specific clinical features. [75] [76] [77] Interestingly, the TRIBUTE study did not find a significant relationship between both treatment arms and the incidence of pneumonia, 72 but the IMPACT trial showed a higher incidence of pneumonia in the ICS-containing regimens and an increased risk of pneumonia as assessed in the time-to-first event analysis. 73 To make things more complex, corticosteroids, either systemic or inhaled, have been associated with a better prognosis of pneumonia 78, 79 and the reason why ICS reduce exacerbations (the majority of which are related to an infective cause) but increase pneumonia has not been fully elucidated. 47 Osteoporosis and the use of ICS pose another challenge. In the last decade, different observational studies have shown a relationship between the use of ICS and an increased risk for low bone mineral density or fractures. 80 However, well-designed prospective randomized trials have failed to find such association. 74 To make things more complex, it has been described that the progression of COPD does not correlate with the progression of annual change in bone mineral density, 81 and a potential preventive role of ICS for osteoporosis has been proposed. 82, 83 This relationship is complex and there are several hypotheses and confounding factors 84, 85 that should be carefully evaluated in an ad hoc study in the future.
Although the above-mentioned co-morbidities are not formally considered full contraindications for treatment strategies at present, it is likely that in the future we shall be able to identify data at the patient level, which would then influence treatment selection in specific patients.
STEP DOWN FROM TRIPLE THERAPY TO DOUBLE BRONCHODILATION
ICS discontinuation may be encountered in two main clinical scenarios.
First scenario: Uncontrolled exacerbations
The first clinical scenario involves patients in whom the number of exacerbations could not be controlled with ICS. As discussed earlier, several co-morbidities present an increased risk of worsening exacerbations and, of these, only ACO is treated with ICS. Accordingly, the GOLD 2017 guidelines recognize that patients with persistent exacerbations despite LABA/LAMA/ICS treatment may discontinue ICS, given the reported lack of efficacy, elevated risk of adverse effects (including pneumonia) and evidence showing no significant harm from withdrawal. 1 Strictly speaking, this scenario has only been evaluated in the Withdrawal of Inhaled Steroids During Optimised bronchodilator Management (WISDOM) trial, 86 in which the authors found that the risk of moderate or severe exacerbation was similar among those who did and did not discontinue ICS, 86 with a slight decrease in lung function that did not worsen over the course of the study. 87 Therefore, evidence regarding the safety of ICS withdrawal in patients with persistent or increasing exacerbations despite receiving triple therapy is limited.
At the patient level, however, the key clinical challenge involves the identification of patients whose conditions would worsen after ICS discontinuation. A previous study identified several subgroups of patients prone to worsening exacerbations after ICS discontinuation, including women, elderly patients, smokers and patients with higher concomitant bronchodilator use. 88 Additionally, the time of the year was also identified as relevant to the discontinuation of ICS. 89 Interestingly, the WISDOM data revealed that a blood eosinophil count might predict a deleterious response to ICS withdrawal. 90 Despite the ongoing debate on the general use of blood eosinophils as a biomarker for treatment selection (see above), the utility of this population in this specific clinical context should be explored further.
Second scenario: Low-risk patients
Since the 2017 version of the GOLD document, patients are stratified by separating lung function from symptoms and exacerbations. The immediate consequence of this change is that patients who were considered high risk due to lung function alone under the GOLD 2016 criteria would now be considered low risk. Interestingly, when analysing the distribution of patients according to GOLD 2016 criteria, the great majority of high-risk patients were classified as such according to lung function. 91 Therefore, the GOLD 2017 classification would be expected to shift a considerable number of previously high-risk patients to the low-risk category. 92 A quantitative analysis of data from previous cohort studies supports this expectation (Fig. 2) .
The implications for this change in patient status are obvious. The number of patients overexposed to ICS 95, 96 may now increase, as many patients receiving high-risk treatment would now be considered low risk and would not be indicated to use ICS.
1 Fortunately, at least four studies of different designs have reported about the safety of ICS withdrawal among low-risk patients. [97] [98] [99] [100] Taken together, the evidence suggests that ICS discontinuation is safe for current low-risk patients. Further studies will need to identify specific patient types through a patient-based analysis to fill in the details.
STEP DOWN FROM DOUBLE TO SINGLE BRONCHODILATION
The transition from double to simple bronchodilation deserves a specific comment in two clinical scenarios. First, the 2017 GOLD guidelines recommend that for patients in group B, treatment could be stepped down to single bronchodilation if the addition of a second bronchodilator did not improve symptoms, 1 although this may be a difficult thing to explore in patients with limited exercise tolerance. In such patients the possibility of symptoms related to co-morbidities should be investigated. 101 Second, a low-symptomatic patient receiving double bronchodilator therapy may need to determine whether to maintain this regimen or to step down to a single LABD. Although common sense suggests against a change in therapy if the symptoms are controlled, no clinical trials have evaluated this type of treatment switch at the patient level.
One aspect that may lead clinicians to rethink a possible step down from double to single bronchodilation is safety. Two relevant safety analyses have been recently published. The first included 31 174 patients from the UK Clinical Practice Research Datalink, 102 which found that the addition of a second LABD was not associated with an increased risk of myocardial infraction, stroke or arrhythmia; however, an elevated risk of heart failure was observed with double therapy (hazard ratio = 1.16; 95% CI = 1.03-1.30). Nonetheless, this was a retrospective database analysis and it has not been borne out in any of the randomized controlled trials of LAMA/LABA therapy. Therefore, this finding warrants further investigations of safety.
The second was a retrospective, observational cohort study of health insurance claims data from which 19 067 patients who received LABA/LAMA or LABA/ICS for COPD were identified. 103 Cardiovascular events in the LABA/LAMA cohort were lower in the LABA/ICS group, with no significant difference in the risk of cerebrovascular events. Therefore, LABA/LAMA fared well versus LABA/ICS in a comparison of safety.
CONCLUSIONS
As reflected in this review, changes to the management of COPD that address some of the stated challenges at the patient level are underway. Although numerous large clinical trials have aimed to address a range of clinical objectives, in many clinical situations, common sense and the available evidence should be used to make the best possible decision at the patient level. In our present review, we have discussed only inhaled treatments. However, another review may discuss oral treatments, such as methylxanthines, 104 phosphodiesterase inhibitors, 105 mucolytics 106 or antibiotics, 107 which have also been the subject of controversy. We hope that this review will help to highlight the most relevant discussion points regarding the treatment of COPD in a manner that will stimulate and guide related research.
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